CVS Health (CVS) Stock Looks Fully Valued As Returns Shine And Earnings Look Rich
CVS Health stock has delivered a strong 74.4% return over the past year, yet its valuation checks lean expensive and suggest the current share price may already be pricing in a lot of good news.
- A 74.4% one year gain can signal renewed confidence in CVS Health, but it also raises the bar for what future performance needs to justify the current price.
- Regulatory settlements around insulin pricing and Omnicare, along with ongoing legal and compliance obligations, may affect how investors assess the durability and quality of CVS Health's future cash flows.
- With CVS Health scoring only 2 out of 6 on broader valuation checks, the stock currently looks more like a higher expectation story than a clear bargain.
The issue now is whether CVS Health's recent run and ongoing legal and regulatory overhangs leave enough valuation upside to compensate for the risks investors are taking on.
Does CVS Health Look Pricey on Earnings?
The P/E ratio is a useful way to think about what you are paying for each dollar of CVS Health earnings. Right now, CVS Health trades on a P/E of about 46.3x, which is well above the Healthcare industry average of 25.1x and also higher than the peer group average of 19.8x.
The tailored fair P/E multiple for CVS Health, which factors in its business profile and risks, is estimated at 40.7x. That leaves the current 46.3x P/E sitting meaningfully above this fair level. This suggests investors are already assigning a premium for the company despite the regulatory settlements and legal overhangs that remain in play. Even after the positive attention around its FTC settlement and ongoing focus on affordability, the market multiple implies rich expectations compared with sector norms and what the model flags as a more balanced earnings-based valuation.
On the P/E multiple, CVS Health stock screens as overvalued, with its earnings already priced at a premium to both peers and a more tailored fair value level.
See what the numbers say about this price — find out in our valuation breakdown.
The CVS Health Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for CVS Health pick up where the P/E puzzle leaves off by explaining which paths for CVS Health's revenue, margins and earnings would need to occur for the stock to be worth materially more or less than it is today on the market. Instead of a single ratio or model output, they show the future that figure relies on so you can watch how the real business lines up with those assumptions over time on the Community page.
Community views on CVS Health sit on very different paths, depending on how much weight you put on its integrated healthcare model versus ongoing cost and execution risks.
Bull case: roughly fairly valued
"Expansion of value-based care models, both internally and through partnerships, aligns CVS Health with the shifting reimbursement environment, rewarding coordinated, preventive care and enabling CVS to benefit from improved clinical outcomes, cost containment, and improved long-term profitability…"
Read the full Bull Case to see why CVS Health could be undervalued
Bear case: roughly fairly valued
"The result has been increasing uncertainty, thanks in part to leadership changes and rising medical costs, with investors questioning whether CVS can indeed make the shift from retail to a healthcare model…"
Read the full Bear Case to see why CVS Health could be overvalued
Do you think there's more to the story for CVS Health? Head over to our Community to see what others are saying!
The Bottom Line
For CVS Health, the current market multiples suggest the stock is priced on the expensive side, with investors already paying up for its earnings relative to sector norms and tailored fair value estimates. The broader valuation checks are weak, which points to less room for error if the business stumbles or if sentiment cools. From here, the key question is whether CVS Health can deliver on its integrated healthcare ambitions and manage regulatory and legal risks well enough to sustain that premium without leaving investors exposed to a sharp reset in expectations.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com